NCTId,BriefTitle,OverallStatus,StudyType,Phases,Conditions,LeadSponsorName,StartDate,StudyFirstPostDate,LastUpdatePostDate,Timestamp
NCT04184882,"A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)",TERMINATED,INTERVENTIONAL,PHASE1,Duchenne Muscular Dystrophy (DMD),Astellas Pharma Inc,2021-02-24,2019-12-04,2024-10-22,2024-11-05T07:17:52.873621
NCT03179631,Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy,COMPLETED,INTERVENTIONAL,PHASE3,"Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn",PTC Therapeutics,2017-07-06,2017-06-07,2024-01-18,2024-11-05T07:17:52.873621
NCT02018731,L-citrulline and Metformin in Becker's Muscular Dystrophy,COMPLETED,INTERVENTIONAL,PHASE2,Becker's Muscular Dystrophy (BMD),"University Hospital, Basel, Switzerland",2013-06,2013-12-23,2016-05-16,2024-11-05T07:17:52.873621
